tetano
Editor, Senior Moderator
Antiviral Res
. 2024 Jun 17:105938.
doi: 10.1016/j.antiviral.2024.105938. Online ahead of print. Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons
Yuyang Sun[SUP] 1 [/SUP], Keita Wagatsuma[SUP] 2 [/SUP], Reiko Saito[SUP] 2 [/SUP], Isamu Sato[SUP] 3 [/SUP], Takashi Kawashima[SUP] 4 [/SUP], Tadashi Saito[SUP] 5 [/SUP], Yashushi Shimada[SUP] 6 [/SUP], Yasuhiko Ono[SUP] 7 [/SUP], Fujio Kakuya[SUP] 8 [/SUP], Michiyoshi Minato[SUP] 9 [/SUP], Naoki Kodo[SUP] 10 [/SUP], Eitaro Suzuki[SUP] 11 [/SUP], Akito Kitano[SUP] 12 [/SUP], Irina Chon[SUP] 2 [/SUP], Wint Wint Phyu[SUP] 2 [/SUP], Jiaming Li[SUP] 2 [/SUP], Hisami Watanabe[SUP] 13 [/SUP]
Affiliations
We compared the duration of fever in children infected with A(H1N1)pdm09, A(H3N2), or influenza B viruses following treatment with baloxavir marboxil (baloxavir) or neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, or laninamivir). This observational study was conducted at 10 outpatient clinics across 9 prefectures in Japan during the 2012-2013 and 2019-2020 influenza seasons. Patients with influenza rapid antigen test positive were treated with one of four anti-influenza drugs. The type/subtype of influenza viruses were identified from MDCK or MDCK SIAT1 cell-grown samples using two-step real-time PCR. Daily self-reported body temperature after treatment were used to evaluate the duration of fever by treatment group and various underlying factors. Among 1,742 patients < 19 years old analyzed, 452 (26.0%) were A(H1N1)pdm09, 827 (48.0%) A(H3N2), and 463 (26.0%) influenza B virus infections. Among fours treatment groups, baloxavir showed a shorter median duration of fever compared to oseltamivir in univariate analysis for A(H1N1)pdm09 virus infections (baloxavir, 22.0 h versus oseltamivir, 26.7 h, P < 0.05; laninamivir, 25.5 h, and zanamivir, 25.0 h). However, this difference was not significant in multivariable analyses. For A(H3N2) virus infections, there were no statistically significant differences observed (20.3, 21.0, 22.0, and 19.0 h) uni- and multivariable analyses. For influenza B, baloxavir shortened the fever duration by approximately 15 h than NAIs (20.3, 35.0, 34.3, and 34.1 h), as supported by uni- and multivariable analyses. Baloxavir seems to have comparable clinical effectiveness with NAIs on influenza A but can be more effective for treating pediatric influenza B virus infections than NAIs.
Keywords: antiviral treatment; baloxavir marboxil; clinical effectiveness; influenza virus; neuraminidase inhibitors.
. 2024 Jun 17:105938.
doi: 10.1016/j.antiviral.2024.105938. Online ahead of print. Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons
Yuyang Sun[SUP] 1 [/SUP], Keita Wagatsuma[SUP] 2 [/SUP], Reiko Saito[SUP] 2 [/SUP], Isamu Sato[SUP] 3 [/SUP], Takashi Kawashima[SUP] 4 [/SUP], Tadashi Saito[SUP] 5 [/SUP], Yashushi Shimada[SUP] 6 [/SUP], Yasuhiko Ono[SUP] 7 [/SUP], Fujio Kakuya[SUP] 8 [/SUP], Michiyoshi Minato[SUP] 9 [/SUP], Naoki Kodo[SUP] 10 [/SUP], Eitaro Suzuki[SUP] 11 [/SUP], Akito Kitano[SUP] 12 [/SUP], Irina Chon[SUP] 2 [/SUP], Wint Wint Phyu[SUP] 2 [/SUP], Jiaming Li[SUP] 2 [/SUP], Hisami Watanabe[SUP] 13 [/SUP]
Affiliations
- PMID: 38897317
- DOI: 10.1016/j.antiviral.2024.105938
We compared the duration of fever in children infected with A(H1N1)pdm09, A(H3N2), or influenza B viruses following treatment with baloxavir marboxil (baloxavir) or neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, or laninamivir). This observational study was conducted at 10 outpatient clinics across 9 prefectures in Japan during the 2012-2013 and 2019-2020 influenza seasons. Patients with influenza rapid antigen test positive were treated with one of four anti-influenza drugs. The type/subtype of influenza viruses were identified from MDCK or MDCK SIAT1 cell-grown samples using two-step real-time PCR. Daily self-reported body temperature after treatment were used to evaluate the duration of fever by treatment group and various underlying factors. Among 1,742 patients < 19 years old analyzed, 452 (26.0%) were A(H1N1)pdm09, 827 (48.0%) A(H3N2), and 463 (26.0%) influenza B virus infections. Among fours treatment groups, baloxavir showed a shorter median duration of fever compared to oseltamivir in univariate analysis for A(H1N1)pdm09 virus infections (baloxavir, 22.0 h versus oseltamivir, 26.7 h, P < 0.05; laninamivir, 25.5 h, and zanamivir, 25.0 h). However, this difference was not significant in multivariable analyses. For A(H3N2) virus infections, there were no statistically significant differences observed (20.3, 21.0, 22.0, and 19.0 h) uni- and multivariable analyses. For influenza B, baloxavir shortened the fever duration by approximately 15 h than NAIs (20.3, 35.0, 34.3, and 34.1 h), as supported by uni- and multivariable analyses. Baloxavir seems to have comparable clinical effectiveness with NAIs on influenza A but can be more effective for treating pediatric influenza B virus infections than NAIs.
Keywords: antiviral treatment; baloxavir marboxil; clinical effectiveness; influenza virus; neuraminidase inhibitors.